{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:33:27Z","timestamp":1778589207213,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/srep05663","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T09:04:03Z","timestamp":1405069443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Hyperhomocysteinemia is one of the risk factors associated with cerebrovascular stiffness in hypertensive patients, especially elderly males"],"prefix":"10.1038","volume":"4","author":[{"given":"Takafumi","family":"Okura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Irita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daijiro","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Kukida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Tanino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zouwei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitsuo","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,11]]},"reference":[{"key":"BFsrep05663_CR1","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1161\/01.ATV.20.7.1704","volume":"20","author":"SH Mudd","year":"2002","unstructured":"Mudd, S. H. et al. Homocysteine and its disulfide derivatives: A suggested consensus terminology. Arterioscler Thromb Vasc Biol. 20, 1704\u20131706 (2002).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"BFsrep05663_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJM199707243370403","volume":"337","author":"O Nyfard","year":"1997","unstructured":"Nyfard, O. et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337, 230\u2013236 (1997).","journal-title":"N Engl J Med."},{"key":"BFsrep05663_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7326\/0003-4819-140-2-200401200-00009","volume":"140","author":"M Soinio","year":"2004","unstructured":"Soinio, M. et al. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med. 140, 94\u2013100 (2004).","journal-title":"Ann Intern Med."},{"key":"BFsrep05663_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s100169900037","volume":"11","author":"SW Cheng","year":"1997","unstructured":"Cheng, S. W., Ting, A. C. & Wong, J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg. 11, 217\u2013223 (1997).","journal-title":"Ann Vasc Surg."},{"key":"BFsrep05663_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S0140-6736(95)92407-8","volume":"346","author":"IJ Perry","year":"1995","unstructured":"Perry, I. J. et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346, 1395\u20131398 (1995).","journal-title":"Lancet."},{"key":"BFsrep05663_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.12.007","volume":"17","author":"A Towfighi","year":"2008","unstructured":"Towfighi, A., Saver, J. L., Engelhardt, R. & Ovbiagele, B. Factors associated with the steep increase in late-midlife stroke occurrence among US men. J Stroke Cerebrovasc Dis. 17, 165\u2013168 (2008).","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"BFsrep05663_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1056\/NEJM199502023320502","volume":"332","author":"J Selhub","year":"1995","unstructured":"Selhub, J. et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 332, 286\u2013291 (1995).","journal-title":"N Engl J Med."},{"key":"BFsrep05663_CR8","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1161\/01.CIR.99.18.2383","volume":"99","author":"BM McQuillan","year":"1999","unstructured":"McQuillan, B. M., Beilby, J. P., Nidorf, M., Thompson, P. L. & Hung, J. Hyperhomocysteinemia but not the c677t mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The perth carotid ultrasound disease assessment study (cudas). Circulation. 99, 2383\u20132388 (1999).","journal-title":"Circulation."},{"key":"BFsrep05663_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/STROKEAHA.110.595546","volume":"42","author":"SJ Kim","year":"2011","unstructured":"Kim, S. J. et al. Biomarkers of asymptomatic carotid stenosis in patients undergoing coronary artery bypass grafting. Stroke. 42, 734\u2013739 (2011).","journal-title":"Stroke."},{"key":"BFsrep05663_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.med.60.041807.123308","volume":"60","author":"BA Maron","year":"2009","unstructured":"Maron, B. A. & Loscalzo, J. The treatment of hyperhomocystenemia. Annu Rev Med. 60, 39\u201354 (2009).","journal-title":"Annu Rev Med."},{"key":"BFsrep05663_CR11","first-page":"3203","volume":"119","author":"J Loscalzo","year":"2009","unstructured":"Loscalzo, J. Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology. J Clin Invest. 119, 3203\u20133205 (2009).","journal-title":"J Clin Invest."},{"key":"BFsrep05663_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jama.291.5.565","volume":"291","author":"JF Toole","year":"2004","unstructured":"Toole, J. F. et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: The vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565\u2013575 (2004).","journal-title":"JAMA"},{"key":"BFsrep05663_CR13","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMoa060900","volume":"354","author":"E Lonn","year":"2006","unstructured":"Lonn, E. et al. Heart outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 354, 1567\u20131577 (2006).","journal-title":"N Engl J Med."},{"key":"BFsrep05663_CR14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJMoa055227","volume":"354","author":"KH B\u00f8naa","year":"2006","unstructured":"B\u00f8naa, K. H. et al. NORVIT Trial Investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 354, 1578\u20131588 (2006).","journal-title":"N Engl J Med."},{"key":"BFsrep05663_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/HJH.0b013e328352aba6","volume":"30","author":"CR Cardoso","year":"2012","unstructured":"Cardoso, C. R. et al. Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients. J Hypertens. 30, 940\u2013947 (2012).","journal-title":"J Hypertens."},{"key":"BFsrep05663_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00004872-200202000-00001","volume":"20","author":"A Simon","year":"2002","unstructured":"Simon, A. et al. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 20, 159\u2013169 (2002).","journal-title":"J Hypertens."},{"key":"BFsrep05663_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199901073400103","volume":"340","author":"DH O'Leary","year":"1999","unstructured":"O'Leary, D. H. et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340, 14\u201322 (1999).","journal-title":"N Engl J Med"},{"key":"BFsrep05663_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/oxfordjournals.aje.a010233","volume":"151","author":"LE Chambless","year":"2000","unstructured":"Chambless, L. E. et al. Carotid wall thickness is predictive of incident clinical stroke. The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 151, 478\u2013487 (2000).","journal-title":"Am J Epidemiol"},{"key":"BFsrep05663_CR19","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1161\/01.STR.0000202589.47401.c6","volume":"37","author":"D Staub","year":"2006","unstructured":"Staub, D. et al. Prediction of cardiovascular morbidity and mortality: comparison of the internal carotid artery resistive index with the common carotid artery intima-media thickness. Stroke. 37, 800\u2013805 (2006).","journal-title":"Stroke."},{"key":"BFsrep05663_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1291\/hypres.28.797","volume":"28","author":"M Kurata","year":"2005","unstructured":"Kurata, M., Okura, T., Watanabe, S. & Higaki, J. Association between carotid hemodynamics and asymptomatic white and gray matter lesions in patients with essential hypertension. Hypertens Res. 28, 797\u2013803 (2005).","journal-title":"Hypertens Res."},{"key":"BFsrep05663_CR21","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/HJH.0b013e32835eb6b9","volume":"31","author":"SC van Dijk","year":"2013","unstructured":"van Dijk, S. C. et al. Homocysteine level is associated with aortic stiffness in elderly: cross-sectional results from the B-PROOF study. J Hypertens. 31, 952\u2013959 (2013).","journal-title":"J Hypertens."},{"key":"BFsrep05663_CR22","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1161\/STROKEAHA.109.558403","volume":"40","author":"MH Lim","year":"2009","unstructured":"Lim, M. H., Cho, Y. I. & Jeong, S. K. Homocysteine and pulsatility index of cerebral arteries. Stroke 40, 3216\u20133220 (2009).","journal-title":"Stroke"},{"key":"BFsrep05663_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ajcn\/69.3.482","volume":"69","author":"PF Jacques","year":"1999","unstructured":"Jacques, P. F. et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 69, 482\u2013489 (1999).","journal-title":"Am J Clin Nutr."},{"key":"BFsrep05663_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jvs.2011.07.031","volume":"54","author":"JJ Ricotta","year":"2011","unstructured":"Ricotta, J. J. et al. Up dated society for vascular surgery guidelines for management of extracranial carotid disease. J Vasc Surg. 54, e1\u2013e31 (2011).","journal-title":"J Vasc Surg."},{"key":"BFsrep05663_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 53, 982\u2013992 (2009).","journal-title":"Am J Kidney Dis."},{"key":"BFsrep05663_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/sj.jhh.1001898","volume":"19","author":"S Manabe","year":"2005","unstructured":"Manabe, S., Okura, T., Watanabe, S. & Higaki, J. Association between carotid haemodynamics and inflammation in patients with essential hypertension. J Hum Hypertens. 19, 787\u2013791 (2005).","journal-title":"J Hum Hypertens."},{"key":"BFsrep05663_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2214\/ajr.148.4.759","volume":"148","author":"MD Rifkin","year":"1987","unstructured":"Rifkin, M. D. et al. Evaluation of renal transplant rejection by duplex Doppler examination: value of the resistive index. Am J Roentgenol. 148, 759\u2013762 (1987).","journal-title":"Am J Roentgenol."},{"key":"BFsrep05663_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/10641960802279108","volume":"30","author":"T Okura","year":"2008","unstructured":"Okura, T. et al. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Clin Exp Hypertens. 30, 415\u2013422 (2008).","journal-title":"Clin Exp Hypertens."},{"key":"BFsrep05663_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.mehy.2011.09.009","volume":"77","author":"M Hoffman","year":"2011","unstructured":"Hoffman, M. Hypothesis: hyperhomocysteinemia is an indicator of oxidative stress. Med Hypotheses. 77, 1088\u20131093 (2011).","journal-title":"Med Hypotheses."},{"key":"BFsrep05663_CR30","first-page":"1","volume":"61","author":"KS McCully","year":"1970","unstructured":"McCully, K. S. & Ragsdale, B. D. Production of arteriosclerosis by homocysteinemia. Am J Pathol. 61, 1\u201311 (1970).","journal-title":"Am J Pathol."},{"key":"BFsrep05663_CR31","first-page":"CD006612","volume":"1","author":"AJ Marti-Carvajal","year":"2013","unstructured":"Marti-Carvajal, A. J. et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 1, CD006612 (2013).","journal-title":"Cochrane Database Syst Rev."},{"key":"BFsrep05663_CR32","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1001\/jama.2011.1834","volume":"306","author":"JD Spence","year":"2011","unstructured":"Spence, J. D. & Stampfer, M. J. Understanding the complexity of homocysteine lowering with vitamins: The potential role of subgroup analyses. JAMA. 306, 2610\u20132611 (2011).","journal-title":"JAMA."},{"key":"BFsrep05663_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1515\/cclm-2012-0465","volume":"51","author":"JD Spence","year":"2013","unstructured":"Spence, J. D. B vitamin therapy for homocysteine: Renal function and vitamin B12 determine cardiovascular outcomes. Clin Chem Lab Med. 51, 633\u2013637 (2013).","journal-title":"Clin Chem Lab Med."},{"key":"BFsrep05663_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1755-5922.2011.00266.x","volume":"30","author":"B Debreceni","year":"2012","unstructured":"Debreceni, B. & Debreceni, L. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? Cardiovasc Ther. 30, 227\u2013233 (2012).","journal-title":"Cardiovasc Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep05663","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep05663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep05663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T08:03:08Z","timestamp":1672992188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep05663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,11]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,17]]}},"alternative-id":["BFsrep05663"],"URL":"https:\/\/doi.org\/10.1038\/srep05663","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,11]]},"assertion":[{"value":"26 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Higaki received research grants and speaker honoraria from Pfizer Inc., Asteras Co., Takeda Pharm Co., Beringer-Ingerheim Japan Co., Daiichi-Sankyo Co., MSD Co., Mochida Pharm Co., Novartis Pharm. Co. and DaiNihon-Sumitomo Co. The other authors have indicated that they have no conflicts of interest with regards to the contents of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5663"}}